By Karen Roman Vivani Medical, Inc. (Nasdaq: VANI) announced it finished the placement of NPM-115, its GLP-1 (exenatide) implant, in the first-in-human clinical trial of its kind. The company also said it achieved full enrollment for this study, which targets...

By Karen Roman Vivani Medical, Inc. (Nasdaq: VANI) said it expects to spin off Cortigent, Inc., its brain implant devices division, as an independent publicly-traded company. Vivani aims to create two companies focused on driving long term value creation in...

By Karen Roman Biopharmaceutical company Medera Inc. said it finished patient dosing in the trial of SRD-001, its gene therapy candidate for heart failure with reduced ejection fraction. Additionally, Medera and Keen Vision Acquisition Corporation (Nasdaq: KVAC) announced they had...

By Daniella Parra Ascentage Pharma (NASDAQ: AAPG; HKEX) said that its drug Olverembatinib is the first China-approved third-generation BCR-ABL inhibitor, and has been approved for certain chronic myeloid leukemia (CML) indications and included in China’s National Reimbursement Drug List. Olverembatinib,...

By Karen Roman Medical tech company Nano-X Imaging Ltd. (Nasdaq: NNOX) said Nanox.ARC, its digital multi-source 3D tomosynthesis imaging system, received CE mark certification in the European market. Nanox.ARC also has FDA clearance for general use in the U.S. and...

By Daniella Parra Jeito Capital said it invested in Callio Therapeutics’ $187M Series A round to support its next-generation multi-payload antibody-drug conjugates (ADCs) for cancer treatment. Callio Therapeutics is a biotechnology company developing multi-payload ADCs that says it aims to...

By Karen Roman Biopharmaceutical company ReAlta Life Sciences said it appointed Andrew Miller, Ph.D., to its Board of Directors. Dr. Miller is the founder of Karuna Therapeutics, acquired by Bristol Myers Squibb for $14 billion in 2024, the company declared....

By Daniella Parra March Biosciences was granted an orphan drug designation from the FDA to MB-105, its CD5-targeted CAR-T cell therapy, which has shown promising safety and efficacy in Phase 1 trials, with a 44% response rate in TCL patients,...

By Daniella Parra Lisata Therapeutics said results from Cohort A of its Phase 2 ASCEND trial showed complete responses in 6.2% of certepetide-treated patients, compared to 0% in the placebo group. The company said it evaluated its investigational drug certepetide...

By Daniella Parra Araris Biotech AG, a Swiss oncology biotech firm, has partnered with Chugai Pharmaceutical to develop advanced antibody-drug conjugates (ADCs) using Araris’ AraLinQ platform, the company said. The collaboration aims to create ADCs in cancer treatments by incorporating...